Bristol-Myers: acquisition of IFM Therapeutics complete.
(CercleFinance.com) - Bristol-Myers Squibb said late on Thursday that it has completed the acquisition of IFM Therapeutics, a Boston-Based biopharmaceutical firm that is focused on enhancing the immune system for treating cancer.
IFM's team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, autoimmunity, and inflammatory disorders.
The US pharma giant also released the results of two Phase 3 pivotal trials showing survival benefit in patients with advanced non-small cell lung cancer treated with Opdivo.
The drug nearly tripled and doubled the patients alive at three years compared to anti-cancer drug docetaxel in both studies.
This data will be presented at the European Society for Medical Oncology Congress in Madrid on Sunday.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
IFM's team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, autoimmunity, and inflammatory disorders.
The US pharma giant also released the results of two Phase 3 pivotal trials showing survival benefit in patients with advanced non-small cell lung cancer treated with Opdivo.
The drug nearly tripled and doubled the patients alive at three years compared to anti-cancer drug docetaxel in both studies.
This data will be presented at the European Society for Medical Oncology Congress in Madrid on Sunday.
Copyright (c) 2017 CercleFinance.com. All rights reserved.